Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines
| Autor: | Franklin Hendrick, Amer M. Zeidan, Xuehua Ke, Sheila R. Weiss, Amy J. Davidoff, Maria R. Baer, Steven D. Gore |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Darbepoetin alfa Anemia medicine.drug_class Population Medicare Article hemic and lymphatic diseases Internal medicine Epidemiology medicine Surveillance Epidemiology and End Results Humans Registries Practice Patterns Physicians' education Erythropoietin Aged Aged 80 and over education.field_of_study business.industry Myelodysplastic syndromes Epoetin alfa Hematology Middle Aged medicine.disease Erythropoiesis-stimulating agent Drug Utilization Recombinant Proteins United States Epoetin Alfa Oncology Myelodysplastic Syndromes Practice Guidelines as Topic Hematinics Physical therapy Female Guideline Adherence business medicine.drug |
| Zdroj: | Leukemia Research. 37:675-680 |
| ISSN: | 0145-2126 |
| Popis: | Erythropoiesis-stimulating agents (ESA) are used commonly to reduce symptomatic anemia in patients with myelodysplastic syndromes (MDS). We assessed population-based patterns of ESA use relative to treatment guidelines using data from the Surveillance, Epidemiology, and End Results (SEER) registries, with linked Medicare claims providing detailed treatment data from 2001 through 2005. The study found widespread use (62%) of ESA in Medicare beneficiaries with MDS. Similar ESA use rates regardless of risk status, low frequency (45%) of serum erythropoietin determination prior to ESA initiation, and high prevalence (60.4%) of short-duration ESA episodes suggest clinically important discrepancies between actual practice and guideline-recommended therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect